<DOC>
	<DOCNO>NCT02433288</DOCNO>
	<brief_summary>This randomize , two-arm , open label , Phase IV clinical trial evaluate provision smart phone-based patient support tool prolongs patient 's rosuvastatin treatment duration .</brief_summary>
	<brief_title>Rosuvastatin Adherence App Study China</brief_title>
	<detailed_description>This randomise , two-arm , open , Phase IV clinical trial evaluate provision smart phone-based patient support tool prolongs patient 's rosuvastatin treatment duration . Patients diagnose dyslipidemia hyperlipidemia high risk treat rosuvastatin offer participation study . Patients accept sign Informed Consent randomise one two study group : - Active group : In group , patient access smart phone-based patient support tool . The smart phone application use patient ' smart phone contain patient support tool question clinical evaluation form Rosuvastatin Adherence questionnaire ( RAQ ) , Beliefs Medicine Questionnaire - General ( BMQ-G ) , Lifestyle questionnaire ( LSQ ) disease understanding , lifestyle treatment awareness . Patients Active group also receive feedback daily rosuvastatin treatment enter patient support tool . - Control group : In group patient additional support beyond commonly practiced patient information , i.e . patient access smart phone-based patient support tool . However , smart phone application use prompt patient question clinical evaluation ( RAQ , BMQ-G LSQ ) . In study , rosuvastatin dispense study participant i.e . patient purchase rosuvastatin prescription normal practice . All assessment study ( include blood sample lipid profile ) use guide treatment patient study .</detailed_description>
	<mesh_term>Dyslipidemias</mesh_term>
	<mesh_term>Hyperlipidemias</mesh_term>
	<mesh_term>Rosuvastatin Calcium</mesh_term>
	<criteria>Provision inform consent prior study specific procedure Female male age 1880 year , diagnose dyslipidemia hyperlipidemia high risk prescribe rosuvastatin Dyslipidemia hyperlipidemia define : LDLC≥2.6 mmol/L TG &lt; 4.52mmol/L High risk complies follow : Documented cardiovascular disease ( CVD ) invasive noninvasive testing ( coronary angiography , nuclear imaging , stress echocardiography , carotid plaque ultrasound ) , previous myocardial infarction ( MI ) , acute coronary syndrome ( ACS ) , coronary revascularization [ percutaneous coronary intervention ( PCI ) , coronary artery bypass graft ( CABG ) ] arterial revascularization procedure , ischaemic stroke peripheral arterial disease ( PAD ) . Patients type 2 diabetes , patient type 1 diabetes target organ damage ( microalbuminuria ) . Patients moderate severe chronic kidney disease [ ( CKD ) , glomerular filtration rate ( GFR ) &lt; 60 mL/min/1.73 m2 ] . Patients must smart phone compatible patient support tool clinical evaluation questionnaire disposal comfortable use interactive smart phone application . The required specification phone determine complete test . Ability read , understand write Chinese . Statinnaïve statin use last 4 week prior enrolment except event patient may receive 7 dos statins current hospitalization enrollment . Involvement plan and/or conduct study ( applies AstraZeneca staff and/or staff study site ) Previous enrolment randomisation present study Participation another clinical study investigational product device last 30 day exclude prospective/retrospective register base study require extra visit addition ordinary health care . Patients withdraw study reason reenter study . Patients rosuvastatin contraindicated i.e . patient hypersensitivity rosuvastatin excipients . patient active liver disease include unexplained , persistent elevation serum transaminase serum transaminase elevation exceed 3 x upper limit normal ( ULN ) . patient severe renal impairment ( creatinine clearance &lt; 30 ml/min ) . patient myopathy . patient receive concomitant cyclosporin . female pregnancy lactation woman childbearing potential use appropriate contraceptive measure . Significant medical psychological condition , opinion Investigator , would compromise patient 's safety successful participation study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>smart phone-based</keyword>
	<keyword>rosuvastatin</keyword>
	<keyword>duration treatment</keyword>
	<keyword>Treatment adherence</keyword>
</DOC>